MVIC offers preclinical inhalation studies through its member company Truly Labs. Now the preclinical inhalation activities at Truly Labs have moved to a better and more dedicated laboratory. This enables a higher capacity for inhalation studies. ”Since we have experienced an increased interest in the development of inhaled drug delivery from customers, we are very happy to offer a dedicated laboratory for inhalation studies”, says Karin von Wachenfeldt, CEO at Truly Labs.
The inhalation laboratory will be used for preclinical inhalation studies with optimisation of wet and dry powder formulations (particle generation, particle size measurements, deposition predictions) and subsequent PK, PD and PK/PD studies.